Can I Take Zinc With Farxiga (Dapagliflozin)?

Dapagliflozin, marketed as Farxiga, is an SGLT2 (sodium-glucose cotransporter-2) inhibitor that carries FDA approval for treating type 2 diabetes, heart failure, and chronic kidney disease. Unlike dapagliflozin and other prescription drugs, zinc is sold over-the-counter as a mineral supplement and does not undergo FDA review for potential drug interactions.

No published pharmacokinetic study has identified a direct drug-supplement interaction between dapagliflozin and zinc, and zinc does not appear as an interaction in the current FDA-approved Farxiga prescribing information. The more relevant question for most people is not whether the two conflict, but whether taking zinc long-term at supplement doses creates its own risks, such as copper depletion, that need monitoring independent of Farxiga.

What is actually known versus assumed here

This is the core, quotable answer: dapagliflozin (Farxiga) is cleared primarily through glucuronidation by UGT1A9, and zinc has no recognized effect on that enzyme, so a pharmacokinetic interaction is not expected and none has been reported in the drug's FDA label. Zinc's main independent risks, most notably copper depletion at chronically high intakes, are unrelated to dapagliflozin and would apply whether or not a person takes an SGLT2 inhibitor. Anyone combining the two should still tell their prescriber, because supplement use is not something the label can account for on an individual basis.

Is there a pharmacokinetic interaction?

Dapagliflozin is absorbed in the upper gastrointestinal tract and metabolized mainly by the liver enzyme UGT1A9. Zinc does not inhibit or induce this enzyme, and no published interaction study has tested the combination directly. The FDA label for Farxiga does not list zinc, or minerals generally, among its drug interactions.

A theoretical, unproven concern is that any mineral taken at the same time as an oral medication could slightly slow absorption of one or both compounds through simple competition for gastric emptying and gut transit. This applies to many mineral-drug combinations and is not specific to dapagliflozin. It is also not the kind of interaction seen with true chelating agents like tetracyclines or fluoroquinolones, where zinc binding is well documented and clinically meaningful.

A two-hour separation between zinc and Farxiga is a reasonable, low-cost precaution. It is not a requirement based on demonstrated harm, because no demonstrated harm from co-administration exists in the literature reviewed for this page.

Does zinc affect blood sugar in a way that matters with Farxiga?

Zinc is a cofactor in insulin storage inside pancreatic beta cells, and low zinc status has been associated with higher blood glucose in observational and small trial data in people with type 2 diabetes. Some systematic reviews have reported that zinc supplementation modestly lowers fasting glucose in people with type 2 diabetes, though the exact magnitude varies across studies and the trial quality is mixed. Readers should treat any single average-reduction figure with caution unless it can be checked against the original systematic review, since this kind of number is easy to misstate.

Dapagliflozin lowers blood glucose through an entirely different, insulin-independent mechanism (blocking glucose reabsorption in the kidney). If zinc has any glucose-lowering effect in a given individual, it would be additive rather than conflicting. Because dapagliflozin does not itself cause hypoglycemia in most patients, adding a mild glucose-lowering supplement is unlikely to create dangerous lows, but anyone on additional glucose-lowering medications (sulfonylureas, insulin) should discuss any new supplement with their prescriber before starting it, since the combined effect in that context is less predictable.

The copper question: the more concrete monitoring issue

The clearest, best-supported safety concern with zinc supplementation is not a Farxiga interaction at all. It is copper depletion. Zinc and copper are absorbed through overlapping intestinal pathways, and chronic zinc intake well above recommended amounts is a recognized cause of copper deficiency, which can present as anemia, low white blood cell counts, or neurological symptoms such as numbness. This is why the NIH Office of Dietary Supplements sets a tolerable upper intake level for zinc at 40 mg/day for adults (NIH ODS zinc fact sheet).

This risk exists regardless of what other medications someone takes. It becomes relevant to Farxiga users only because people managing type 2 diabetes or heart failure are more likely to be on multiple supplements and to benefit from periodic lab review.

Evidence-status table: zinc and dapagliflozin

What to verify before combining zinc with Farxiga

• Confirm the total elemental zinc across all supplements and multivitamins does not exceed 40 mg/day without physician guidance.
• Ask your pharmacist to check your full medication list for other zinc-sensitive drugs, particularly tetracyclines or fluoroquinolone antibiotics, where true chelation interactions are established.
• If you plan to supplement zinc above 15 mg/day for more than a few months, ask your prescriber whether a baseline and follow-up serum zinc and copper panel makes sense for you.
• If you have chronic kidney disease stage 4 or 5, mineral handling is already altered by reduced kidney function; discuss any mineral supplement with your nephrologist or prescriber before starting it rather than adjusting on your own.
• Report new fatigue, numbness or tingling in the hands or feet, or unusual infections to your clinician, since these can signal copper deficiency from excess zinc rather than anything related to Farxiga itself.

What guidelines and the label actually say

The FDA-approved Farxiga prescribing information does not list zinc as a drug interaction. The American Diabetes Association's Standards of Care and the Endocrine Society's clinical practice guidelines do not specifically address zinc supplementation alongside SGLT2 inhibitors. Professional endocrinology resources generally recommend that clinicians ask about supplement use at each visit, though they do not single out zinc. Absence of guidance is not the same as a safety endorsement; it reflects that this specific combination has not been formally studied.

A prior version of this page attributed a direct quotation on micronutrient research to a named physician. That quotation could not be verified against a checkable source and has been removed rather than repeated here.

Practical summary for dosing and timing

• Take Farxiga as prescribed, generally once daily in the morning, with or without food.
• If you take zinc, consider dosing it in the evening, at least two hours apart from Farxiga, as a simple precaution rather than a proven necessity.
• Keep total elemental zinc intake at or below 40 mg/day unless a clinician has specifically recommended more for a diagnosed deficiency.
• Zinc citrate, picolinate, and gluconate are generally better absorbed than zinc oxide, which is a formulation consideration rather than a Farxiga-specific one.

This guidance describes general population-level evidence. It is not a substitute for a conversation with the prescriber managing your Farxiga therapy, particularly if you have kidney disease, are on other medications that interact with zinc, or are being evaluated for hormone-related symptoms.